CannabisMedical Publishes Paper on CBD in International Journal... "Potential Application for Degenerative Brain Diseases"

Canabis Medical announced on the 27th that a paper on the "astrocyte protective effect against the neurotoxicity of cannabidiol (CBD)" has been published in the global biotechnology journal Advanced Biology.

The company holds patents related to medical cannabis for degenerative brain diseases and is continuously conducting research and development utilizing medical cannabis in collaboration with the Korea Advanced Institute of Science and Technology (KAIST).

Professor Inseong Choi's team at KAIST suggested the potential application of astrocyte culture medium containing CBD in the field of degenerative brain diseases through this study. The research team analyzed the neurotoxicity of CBD under conditions more similar to the actual brain environment by using a co-culture system of neurons and astrocytes.

As a result, it was observed that astrocytes neutralized the neurotoxicity of CBD, allowing neurons to grow healthily even under high concentrations of CBD. Additionally, when neurons were cultured with astrocyte culture medium treated with CBD, neuronal development was promoted.

A company representative stated, "Our research achievements and expertise on CBD are expected to create synergy with the raw pharmaceutical materials and finished pharmaceutical products know-how of our partners such as Hwail Pharmaceuticals," adding, "We will focus on research and development to quickly enter the rapidly growing medical cannabis market."

Meanwhile, Osung Advanced Materials holds 50.85% of Canabis Medical's shares, and Hwail Pharmaceuticals holds 49.15%.